Q1 FY 2027 saw 10.1% sales growth, margin expansion, and strong India and innovative medicine performance, offset by U.S. generics decline. Organon acquisition is progressing, with related costs impacting results. Management maintains high single-digit growth guidance.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.